On May 29, 2024 Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") reported that the Company will be participating in the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from May 31 to June 4, McCormick Place, Chicago, IL, USA (Press release, MEDIAN Technologies, MAY 29, 2024, View Source;June-4-2024-McCormick-Place-Chicago-IL-USA [SID1234643825]). The Median team, with iCRO and eyonis representatives will be pleased to welcome the ASCO (Free ASCO Whitepaper) participants at booth #15142, South Building, Hall A, McCormick place, from June 1 to 3 (exhibition dates), from 9:00 am to 5:00 pm.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Median Technologies’ abstract selected for online publication is available on the ASCO (Free ASCO Whitepaper) platform:
Abstract #e23010: Double reading performance and the impact of adjudication on progression-free survival estimations: Findings from a lung clinical trial
The FDA recommends Blinded Independent Central Review (BICR) with double reads for imaging in clinical trials, but inter-reader variability raises concerns. Our study examined this variability in lung cancer clinical trials using RECIST. We analyzed 5 phase III trials with 7 readers forming 11 teams, covering 1,017 patients. The study focused on Discrepancy Rate (DR), bias, endorsement rate, and the impact of adjudication on Progression-Free Survival (PFS) estimates. Results showed significant bias among readers, affecting double readings but no correlation between bias and DR. Additionally, adjudication significantly affects PFS estimates. These outcomes highlight the need to improve monitoring in clinical trials.
The ASCO (Free ASCO Whitepaper) Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the largest oncology society in the world. Each year, the ASCO (Free ASCO Whitepaper) conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO (Free ASCO Whitepaper) Annual Meeting: View Source